A recent paper published in Frontiers of Neuroimaging titled 'Synergistic photobiomodulation with 808-nm and 1064-nm lasers to reduce the b-amyloid neurotoxicity in the in vitro Alzheimer’s disease models' (see below) helps to facilitate the application of photobiomodulation with greater specificity and thereby improving clinical efficacy. The paper is a good piece of in vitro (outside the body) evidence for how these two critically important wavelengths influence neuronal cellular metabolic functioning. The findings suggest "...A synergistic PBM effect (with the 808- and 1,064-nm lasers) effectively inhibited the fAb-induced neurotoxicity of neuroblastoma by promoting the viability of neuroblastoma and regulating the intracellular Ca2+ levels of microglia. Moreover, the downregulation of Ca2+ led to microglial polarization with an M2 phenotype, which promotes the fAb phagocytosis, and resulted in the upregulated expression of anti-inflammatory factors and downregulated expression of inflammatory factors.
This underscores the validity of previous studies and approaches that are using transcranial photobiomodulation (tPBM) to mitigate both hypoperfusion and inflammation of people struggling with neurodegeneartive conditions, e.g. Alzheimer's, Parkinson's and ALS.
These bench science insights create important opportunities to further enhance tPBM's clinical efficacy by using these two wavelengths to their greatest therapeutic advantage. Neuronic Devices Ltd. and Quietmind Foundation are now working with our academic research partners in the USA and UK on the next generation tPBM applications that will reflect the results of our applied clinical research in this area.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.